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Functional foods are food products designed and developed to
enhance or promote health or to contribute to reduction of a
specific disease risk.1 A new functional food, a spread or
margarine with added plant sterols, Pro-activ (Unifoods (Pty)
Ltd, Durban), was launched in South Africa during 2000. Plant
sterols are known to inhibit absorption of both exogenous and
endogenous cholesterol, reducing blood cholesterol
concentrations. Levels of plant sterols normally present in the
diet are insufficient to lower blood cholesterol concentrations,
but added to a suitable food vehicle, desired levels may be
obtained. The product was developed in The Netherlands,
motivated by the high incidence of hypercholesterolaemia and
consequent ischaemic heart disease (IHD). The manufacturer
claims that an average daily intake of 20 g of the spread,
providing approximately 2 g plant sterols, will lower total and
low-density lipoprotein (LDL) cholesterol by about 10 - 15%
and the relative risk of IHD by about 25% after 2 years.2
The objectives of this review are to evaluate the need for this
and similar products in South Africa, based on the
epidemiology of dyslipidaemia and IHD in this country; to
evaluate the efficacy of the product based on results of clinical
trials; to assess its safety based on its composition and safety
tests; and to look at practical issues such as target groups,
affordability and long-term surveillance needs.
Need for a cholesterol-lowering
functional food in South Africa
Murray and Lopez3 estimated that globally, in the year 2020,
IHD will be the leading contributor to the burden of disease,
moving from fifth place in 1990 to first place in 2020. Based on
what is known about the epidemiological and health transition
during development and industrialisation of populations, these
authors estimate that annual deaths from cardiovascular
disease will rise from 14 million in 1990 to 23 million in 2020,
accounting for one-third of all deaths worldwide.
Bradshaw and co-workers4 showed that in 1990
cerebrovascular events and IHD were the third and fifth
leading causes of death in South Africa, accounting for 7% and
5% of total deaths in that year.
It is generally accepted that the increase in morbidity and
mortality from chronic diseases in developing populations is,
Functional foods with added plant sterols for 
treatment of hypercholesterolaemia and prevention 
of ischaemic heart disease
H H Vorster, F J Raal, J B Ubbink, A D Marais, M C Rajput, F Y Ntanios
Background. A spread with added plant sterols, Pro-activ, is
marketed in South Africa as an adjunct to low-fat diets for
lowering of total and low-density lipoprotein (LDL)
cholesterol concentrations and to decrease risk of ischaemic
heart disease (IHD).
Objectives. The need for this functional food in South Africa,
its efficacy, safety and target market, are evaluated in this
review.
Results. The high, and probably increasing incidence of
hypercholesterolaemia and cardiovascular disease in South
Africa motivates the need for appropriate functional foods.
There is convincing evidence in the literature that an average
daily intake of about 2 g plant sterols in about 20 g of spread
significantly lowers total and LDL cholesterol concentrations
by approximately 10 - 15%, without influencing high-density
lipoprotein (HDL) cholesterol and triglyceride concentrations.
There is some concern about the effects on absorption of
lipid-soluble vitamins and pro-vitamins, but safety tests
lasting for up to 3 years found no serious adverse effects.
Conclusions. The target market for this spread should be non-
pregnant, non-lactating adults with hypercholesterolaemia
and/or increased risk of IHD. If it is considered for use in
hypercholesterolaemic children, fat-soluble vitamin status
should be monitored. It is recommended that post-marketing
surveillance should be established to determine long-term
effects and safety.
School of Physiology and Nutrition and Lipid Clinic, Potchefstroom University for
Christian Higher Education
H H Vorster, DSc
The Carbohydrate and Lipid Metabolism Research Group, Department of Medicine,
University of the Witwatersrand, Johannesburg
F J Raal, FCP (SA), FRCP, FRCPC, MMed, PhD
Department of Chemical Pathology, University of Pretoria
J B Ubbink, DSc
Department of Medicine, Cape Heart Health Centre and Medical Research Council
Cape Heart Group, University of Cape Town
A D Marais, FCP (SA)
Department of Medicine, R K Khan Hospital, University of Natal, Durban
M C Rajput, FCP (SA), FRCP (UK)
Unilever Health Institute, Unilever Research Vlaardingen, The Netherlands
F Y Ntanios, PhD
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by Cape Town University OpenUCT
in addition to changes in population age structure, a result of
changes in lifestyle during industrialisation and economic
development, namely increased levels of smoking, sedentary
occupations, adoption of high-fat, high-animal protein, low-
fibre diets and increased exposure to stressful situations. All
these factors are known to increase the risk of cardiovascular
disease and specifically IHD because they lead to obesity,
hypertension, diabetes mellitus and hyperlipidaemia, the major
IHD risk factors.
In South Africa, the inter-ethnic difference in prevalence and
incidence of IHD (high in the Indian and white populations,
intermediate in the coloured population and low in black South
Africans) is probably related to differences in patterns of
dyslipidaemia.5 However, several studies6-8 have shown that
hypercholesterolaemia, obesity, hypertension, tobacco smoking
and diabetes mellitus are rapidly increasing in black South
Africans and that the emergence of future IHD is already
apparent.9
The same risk factors also predispose to stroke.10 The highest
documented stroke rates are in coloured and Asian
communities (with age-standardised mortality rates of 
125 - 175/100 000 per annum) and the lowest in the white
community (70/100 000 per annum).10 Unfortunately, few data
are available for black South Africans but small studies suggest
that the stroke rate may be as high as 300/100 000 per annum
in this population.10 In addition to lifestyle-related
dyslipidaemias, major genetic disorders such as familial
hypercholesterolaemia, which powerfully predispose to IHD,
have been well described in many South African communities,
including the black population.9
From the above it is evident that hypercholesterolaemia and
its cardiovascular consequences are well documented, major
public health problems in South Africa. Therefore, two working
groups have recently published guidelines for the diagnosis,
management and prevention of the common dyslipidaemias in
South Africa9,11 and another working group has documented a
‘stroke therapy clinical guideline’.10 In each of these guidelines,
the prevention and treatment of hypercholesterolaemia is
prominent. The two key elements in the management of
hypercholesterolaemia (dyslipidaemia) are lifestyle
modification and the use of appropriate lipid-modifying drugs
in patients at high risk.9 Lifestyle or behaviour modification
includes cessation of tobacco use, a healthy prudent diet,
regular aerobic exercise and weight loss where indicated.
Changes in behaviour are never easy. The low-fat, low-
sodium, high-fibre and high-complex carbohydrate diet
prescribed for the treatment of hypercholesterolaemia11 is
usually less attractive than the typical Western diet in which fat
increases palatability. Consequently, worldwide compliance
with this prudent diet has been disappointing.12 Although there
is no doubt that treatment of hypercholesterolaemia using the
modern statins and/or fibrates reduces both total and
cardiovascular morbidity and mortality, the introduction of
these drugs for treatment of high-risk individuals should be
approached with care, considering the expense, possible side-
effects and the necessity for lifetime compliance.9
It seems, therefore, that based on (i) the high and increasing
prevalence of hypercholesterolaemia, IHD and stroke;
(ii) disappointing compliance with the prudent diet;
and (iii) potential difficulties with drug treatment, there is a
need for specific, palatable and affordable food products that
can effectively and safely lower blood cholesterol levels,
thereby reducing the risk of IHD and stroke. Such a food
should not be seen as a single, magic bullet that will solve a
particular health problem on its own, but rather as part of a
healthy diet (and drug treatment where necessary), which will
enable individuals to comply better with effective treatment
and/or preventive measures.
Plant sterols and functional foods
In 1954 Best and co-workers13 showed that plant sterols, also
known as phytosterols, lower blood cholesterol levels. Sterols
are essential components of cell membranes. Plant sterols are
structurally related to cholesterol, the main animal-derived
sterol, but differ in their side chain configuration. More than 40
plant sterols have been identified. The unsaturated sterols most
frequently found in nature are β-sitosterol, campesterol and
stigmasterol. The stanols are saturated sterols with no double
bonds in the sterol ring. They are less abundant in nature but
can be produced by hydrogenating sterols. Dietary intake of
plant sterols varies from 200 - 300 mg/day in Northern
European countries,14 to 300 - 450 mg/day in Japan15 depending
on the amount of plant food in the diet. Esterification of plant
sterols with fatty acids (e.g. from sunflower oil) increases their
solubility in lipids and improves incorporation in the lipid
phase of food vehicles. Suitable food vehicles will therefore be
those with an oil or fat base such as spreads, salad dressings,
cream cheese and yoghurt. These foods should be eaten in
sufficient quantities in a prudent diet to provide between 1 g
and 3 g plant sterols daily at levels that will not affect the
acceptability and sensory characteristics of the product.
Efficacy of plant sterols in lowering
blood cholesterol
The recent evidence that plant sterols in food vehicles
effectively lower blood (serum or plasma) total and LDL
cholesterol comes from approximately 20 clinical trials in
humans, reviewed by Law16 and Moghadasian and Frohlich.17
Law16 selected 14 randomised, double-blind trials, conducted
between 1993 and 2000 which reported on the difference in
serum cholesterol when using polyunsaturated spreads
(margarines) (N = 9), mayonnaise (N = 3), olive oil (N = 1) or
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butter (N = 1) with and without added plant sterols. Of these, 6
were cross-over trials and 8 were parallel group trials. In total,
473 subjects took a sterol-enriched product and 423 a product
without sterols. The mean ages of the participants varied from
33 to 58 years, and the duration of the trials ranged from 1.4 to
52 weeks. The average daily intake of added plant sterols was
between 0.8 g and 4.0 g. The mean placebo (control)-adjusted
reduction in serum LDL cholesterol varied from 0.20 (95%
confidence interval (CI): 0.10 - 0.31) to 0.64 (CI: 0.06 - 1.22)
mmol/l. The trial with the smallest LDL cholesterol reduction
of 0.20 (CI: 0.10 - 0.31) mmol/l, was that of Hendriks et al.18 in
which 80 subjects with a mean age of 37 years consumed 1.6 g
plant sterols daily in margarine for 3.5 weeks in a cross-over
design. The largest reduction was reported by Jones and co-
workers19 in a parallel trial with 16 experimental and 16 control
subjects with a mean age of 50 years. The experimental subjects
consumed 1.9 g plant sterols daily in margarine for 4 weeks
and showed a reduction of 0.64 (CI: 0.06 - 1.22) mmol/l in LDL
cholesterol when compared with the control group which
consumed margarine without added plant sterols. Law’s16
review pointed out that the LDL cholesterol reductions in these
14 studies were greater in older subjects, and that there is a
dose-response effect continuous up to a dose of about 2 g per
day. This amount of plant sterols added to an average daily
portion of margarine reduced LDL cholesterol by an average of
0.54 mmol/l in subjects aged 50 - 59 years, 0.43 mmol/l in
those aged 40 - 49 years and 0.33 mmol/l in those aged 30 - 39
years. No effects on high-density lipoprotein (HDL) cholesterol
or triglyceride levels were observed.
Moghadasian and Frohlich17 reviewed 16 human studies
published in 1999 and earlier, with a total of 590 subjects. They
found that on average, plant sterol therapy resulted in a 10%
reduction in total cholesterol and a 13% reduction in LDL
cholesterol concentrations. The three trials in Law’s review,16
which compared the efficacy of sterols with that of stanols,
indicated that the stanols may be slightly better. However, the
results were inconclusive. Since publication of these reviews a
number of other human studies20-22 have confirmed the total
cholesterol and LDL cholesterol reductions. One of these
studies21 also compared the effect of unsaturated plant sterol
esters with that of saturated plant stanol esters. This cross-over
clinical trial involving 15 hypercholesterolaemic patients
showed that compared with an ‘unfortified’ margarine,
consuming a margarine with added sterol esters (1.84 g/day)
for 21 days lowered plasma total cholesterol by 13.4%
(significantly: P < 0.05). The observed 10.2% reduction with an
equal dose of the stanol esters was not significant. Cholesterol
absorption was reduced significantly by both sterol and stanol
esters (36.2% and 25.9% respectively). Cholesterol biosynthesis
was reciprocally increased by 53.3% and 37.8% compared with
‘unfortified’ margarine indicating the compensatory
adjustments when cholesterol is not absorbed. Cholesterol
turnover was not influenced by the diet.
It has also been shown23 that plant sterols have an additional,
clinically significant cholesterol-lowering effect when taken as
part of a low-fat diet. In this parallel, double-blind trial, 55
hypercholesterolaemic subjects randomly assigned to three
groups after 4 weeks on a high-fat baseline diet, consumed a
low-fat diet with and without added wood stanol or vegetable
oil stanol-fortified margarines for 8 weeks. The daily mean
stanol intakes were 2.31 g and 2.16 g respectively. Compared
with the low-fat diet, the significant reductions in LDL
cholesterol of the groups consuming the two fortified
margarines were 13.7% and 8.6% greater.
However, some studies24-26 have shown no or only small non-
significant effects of phytosterols. The most recent example is
the study by Denke26 in which a daily dose of 3 g sitostanol
suspended in safflower oil, taken in 12 gelatin capsules by 33
mildly hypercholesterolaemic men on a cholesterol-restricted
diet, had no effect on any of the serum lipids. This author
speculated that the lack of effect could be related to the type of
patients (mildly polygenic hypercholesterolaemic), their low-
cholesterol diet (< 200 mg/day) or the sitostanol preparation
taken as gelatin capsules. If the stanol does not mix sufficiently
with the intestinal contents, significant inhibition of intestinal
cholesterol absorption would not be possible.
From the above it seems reasonable to conclude that there is
convincing evidence from randomised, cross-over or parallel
clinical trials that phytosterols, when added to a functional
food such as a spread or salad dressing, effectively lower total
and LDL cholesterol in adult men and women. These effects are
not dependent on baseline cholesterol levels or background
diet. It also seems that phytosterols do not lower HDL
cholesterol concentrations, nor do they affect triglyceride levels.
The reasons why a few studies could not show cholesterol-
lowering properties may be related to the form of intake, but
more research is needed for clarity.
Other effects and safety issues
The main mechanism thought to be responsible for the total
and LDL cholesterol-lowering effects of functional foods with
added phytosterols, is the inhibition of exogenous (dietary) and
endogenous (biliary) cholesterol absorption in the small
intestine.16,17,21 The serum cholesterol-lowering effect may also
have other associated beneficial, anti-atherogenic effects.17 But
theoretically, the inhibitory effect on intestinal cholesterol and
related lipid absorption (such as fat-soluble vitamins and pro-
vitamins), possible effects on cellular cholesterol and steroid
hormone metabolism and function, possible absorption of
phytosterols, and possible influences of increased phytosterol
concentrations in the large gut (where they are excreted) may
lead to potential toxic or harmful side-effects. A daily portion
of the available functional foods with added phytosterols
provides approximately 10 times more phytosterols than
normally present in the diet. Therefore, the question whether
cholesterol reduction may be hazardous in certain
circumstances should also be addressed.
Because of these possible detrimental effects, the safety of
functional foods with added phytosterols has been extensively
evaluated in a number of clinical trials in humans and rats.
Eleven of the more recent trials20,22,27-35 are summarised in 
Table I. The results of these trials indicate that the small
amounts of phytosterols absorbed are excreted through the bile
and eventually both absorbed and unabsorbed fractions
through the faeces, without affecting large gut microflora,
short-chain fatty acid production or formation of secondary
sterol metabolites. The adrenal glands, ovaries and intestinal
epithelium showed the highest levels of phytosterols in rats
after ingestion of a mixture of labelled sterols. However, no
study could find any evidence that sterol hormone functions or
reproductive characteristics are influenced in the doses tested,
which were generally substantially higher in the animal models
than in humans.
There is concern about the reduction in absorption of lipid-
soluble vitamins and pro-vitamins by phytosterols. No effects
on absorption of vitamins D and K have been observed. The
reductions in vitamin E, α- and β-carotenes are generally non-
significant when standardised for plasma lipids, but the
significant reduction of serum lycopene may be a problem.
Vitamin E as well as α- and β-carotenes and lycopene are
antioxidants, and may be protective against diet-related chronic
diseases.36 Law16 advises that eating more fruit and vegetables,
a major recommendation in many dietary guidelines, would
counter this decrease in absorption of lipid-soluble
antioxidants. The fortification of functional foods with some of
these antioxidants could be another possible solution to the
problem.
The question whether blood cholesterol concentrations can
be reduced to undesirable low levels, needs attention.
Ratnayake and co-workers37 used the haemorrhagic stroke-
prone spontaneously hypertensive rat model (SHRSP rats) to
test the hypothesis that the high concentration of phytosterols
in canola oil compared with soybean oil are responsible for the
shortened lifespan of these rats when fed diets rich in canola
oil. Their results showed that the addition of phytosterols to
the rat diet was associated with a lower red blood cell
membrane deformability index (more rigid membranes), which
correlated with the shorter survival times and cholesterol
concentration. It is possible that the deficiency of membrane
cholesterol and/or replacement of cholesterol by phytosterols
are responsible for this effect. However, in a follow-up study38
the same group of researchers found that this response was
probably unique to the SHRSP rats, since normal healthy
laboratory animals (Wistar rats and gerbils) showed no
alterations in red blood cell deformability, platelet number or
other haematological variables on diets supplemented with
phytosterols. No similar data from human studies could be
found, but Law and co-workers39 assessed the possible hazards
of reducing serum cholesterol in a systematic review of data
from 10 cohort studies, 2 international trials and 28 randomised
trials. They found that the only cause of death attributable to
low serum cholesterol concentration was haemorrhagic stroke.
The excess risk was associated with concentrations below 5
mmol/l (relative risk 1.9, 95% CI: 1.4 - 2.5), affecting about 6%
of people in the Western world. The authors concluded that the
benefit of low serum cholesterol and consequent low IHD risk,
will outweigh the increased risk for haemorrhagic stroke.
However, the above emphasise the importance of targeting
functional foods with powerful cholesterol-lowering properties
to appropriate consumers with high serum cholesterol
concentrations and increased risk of IHD.
In conclusion, the safety evaluation studies,20,22,27-35 some of
which tested phytosterol doses up to 3 g/day for periods up to
3 years, provided no evidence of any toxic effects. The only
concerns seem to be about the possible inhibition of absorption
of some dietary vitamins and pro-vitamins and of increasing
risk of haemorrhagic stroke in individuals with low serum
cholesterol. Both these concerns can be addressed by including
more fruit and vegetables in the diet and by targeting the
phytosterol-rich functional food at individuals with increased
serum cholesterol. Law16 mentioned that phytosterol
margarines have been sold for 3 years in Finland without
evidence of hazard. However, there may be some individuals
with a genetic defect resulting in abnormally high absorption
of phytosterols. These individuals will develop sitosterolaemia,
hypercholesterolaemia and Achilles tendon xanthomas.
Unfortunately, the genetic defect is not well described and it is
not known if individuals heterozygous for this condition
would absorb higher amounts of phytosterols. The Nutrition
Committee of the Council on Nutrition, Physical Activity, and
Metabolism of the American Heart Association advises that
homozygous individuals with tendon xanthomas should be
counselled against the use of products fortified with
phytosterols.40
Practical issues
The nutritional information41,42 and price per 100 g of some
South African margarines and butter are compared with those
of the functional food spread with added phytosterols (Pro-
activ) in Table II. Pro-active and the ‘extra light’ margarine,
products aimed at lowering blood cholesterol concentration
and approved as part of the Heart Foundation eating plan,
have a much higher moisture and therefore lower fat and
energy content than ‘harder’ margarines and butter. Their
ratios of polyunsaturated fatty acids (PUFAs) are also much
higher and their trans fatty acid content is very low or nil. All
these properties are known to decrease serum cholesterol
levels.11 With the added plant sterols at a level of 8 g per 100 g
in Pro-activ, its reported efficacy in lowering circulating total
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Table I. Summary of studies evaluating safety of margarines with added plant sterols
Characteristics
evaluated Study design and methods Results Reference
Oestrogenic activity/potential Binding of plant sterol to oestrogen No evidence of any oestrogenic activity Baker et al.27
receptor, sterol effects on found; no binding to oestrogen receptor,
transcriptional activation of no transcriptional activity and no
oestrogen-responsive genes, and uterotrophic effects demonstrated
effects on oestrogen-responsive
tissues; a mixture of β-sitosterol,
campesterol and stigma sterol
tested in in vitro and in vivo assays
Toxicity in rats: food and water Wistar rats were fed diets containing No treatment-related changes of Hepburn et al.28
consumption, body weights, 0.16, 1.6, 3.2 and 8.1% plant sterols toxicological significance were found
organ weights, histology of for 90 days – equivalent to a dose of
various tissues 6.6 g/kg body weight phytosterol
esters or 4.1 g/kg/day phytosterol
Two-generation reproduction Effects of plant sterols at levels of No effects observed on pup mortality, Waalkens-
performance in male and 0, 1.6, 3.2 and 8.1% (w/w) measured precoital time, mating index, fertility Berendsen et al.29
female Wistar rats in a wide range of reproductive and index, female fecundity index, 
developmental parameters over two gestation index, etc., and pup develop-
successive generations of Wistar rats ment. Also no effects on sexual
maturation parameters. Concluded that
a daily oral dose of up to 1.54 - 5.62 g
phytosterol/kg body weight was the
no observed-effect level
Faecal bile acid and neutral Comparative study with two random- Significant increases in neutral faecal Weststrate et al.30
steroid concentrations of ised parallel groups after run-in period steroids observed as expected in
healthy normolipidaemic consuming 40 g margarine with and phytosterol consumers. No increased
volunteers without added phytosterols for 21 days formation of bile acids or sterol
(males) and 28 days (females). metabolites observed
Background diets standardised. Faecal
neutral steroids, bile acids and sterol 
metabolites measured
Faecal short chain fatty acids A randomised, placebo-controlled, The test group showed significant Ayesh et al.31
(SCFA) bacterial enzyme two-period, parallel dosed study reductions in total and LDL
activities, microflora counts, in healthy men and women, serum cholesterol, faecal lactic
female sex hormones, serum consuming 40 g margarine for 21 acid and serum progesterone. No
cholesterol levels and 28 days with and without other significant treatment effects.
added plant sterols: a test and Although both groups showed
control group significant changes compared with
baseline, none was considered to
be of biological importance
The fate of phytosterols (in Oral dose of 14C-labelled cholesterol, Overall absorption of phytosterols Sanders et al.32
rats) β-sitosterol, β-sitostanol or 3H-labelled low. Eliminated via faeces. Absorption
β-sitostanol, campesterol, campestanol slightly greater in females. Adrenal
or stigmasterol dissolved in sunflower glands, ovaries and intestinal
seed oil. Urine and faecal samples epithelium showed highest levels
collected; tissue and carcass remains and longest retention of radioactivity
examined
Cholesterol and phytosterol Eleven colectomised patients con- Inhibition of cholesterol absorption Miettinen et al.22
metabolism in colectomised sumed margarine with added stanol and lowering of serum cholesterol
patients: serum, biliary and (stanol intake was 2 g/day) for occurred within 1 day of stanol con-
faecal sterols 7 - 18 days sumption; composition of major bile
lipids was unchanged;  gallstone for-
mation unlikely. The small amounts
of plant sterols detected in serum,
excreted through bile
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and LDL cholesterol is not surprising. The major sterols in the
product are campesterol (10 - 40%), stigmasterol (6 - 30%) and
β-sitosterol (30 - 65%).
The South African dietary guidelines for the treatment of
dyslipidaemia11 do not include a specific recommendation
regarding this functional food, probably because the guidelines
were published before the launch of the product. However, it
seems reasonable to recommend that in the prescribed low-
saturated, low trans-fat diet, with or without prescribed drug
treatment, at least 20 g of this margarine should be included in
the daily diet. This amount will provide only 270 kJ and 7 g
total fat and will cost R1.40 per day. Compared with other
spreads it is expensive, but compared with hypolipidaemic
drugs it is extremely cost-effective. The relatively high cost of
the product is because 2 500 parts of raw material are needed
to extract one part of sterol.
Because of the cost, and also because of its high water
content, this spread should not be used for baking or frying of
foods (preparation methods which should be limited in a
cholesterol-lowering diet). The addition of phytosterols to
spreads does not change the taste, consistency or acceptability
of the spread, which ensures that compliance should not be a
problem. It can be expected that such a small change in diet,
replacing an existing spread with the phytosterol-fortified
spread, would result in better compliance than dramatic
dietary interventions.
It is important to emphasise that phytosterol-enriched
spreads should not replace cholesterol-lowering drugs such as
the statins where prescribed. The LDL cholesterol-lowering
properties of the statins are superior, but taken together, the
effects of the two are additive.16
Discussion and conclusion
There is sufficient and convincing evidence that spreads with
added phytosterols effectively lower total and LDL cholesterol
without adverse effects on HDL cholesterol. The ease and
expected high compliance when using these spreads could play
and extremely important role in the prevention of IHD. Law
and co-workers43 analysed 10 prospective, 3 international and
28 randomised control studies to assess by how much and how
quickly a reduction in serum cholesterol concentration will
Table I. (continued)
Characteristics
evaluated Study design and methods Results Reference
Serum carotenoid levels in 60 Randomised, parallel, double-blind In stanol ester groups, α-carotene did Hallikainen et al.33
hypercholesterolaemic patients study with 4 weeks run-in period not change, β-carotene significantly
selected of which 55 completed and 8 weeks experimental: 3 groups lower, but ratio of carotenoids to
the study daily consuming wood stanol ester total cholesterol did not change. No 
(2.31 g) vegetable oil stanol ester change in serum lycopene
(2.16 g) and control margarine.
Serum α-, and β-carotene and
lycopene measured
Effects on lipid-soluble (pro) Randomised, double-blind placebo- Significant decreases in total and LDL Hendriks et al.34
vitamins controlled study using 5 spreads and cholesterol with sterol ingestion. No
4 periods. Plant sterol ingestions were effect on vitamins K1, D, lycopene and
0.83, 1.61 and 3.24 g/day; E, but decreases in α- and β- carotene
N = 100 subjects
Body weight, weight gain of A mixture of vegetable oil-derived No effects in low-dose group but Slesinski et al.35
rats; reproduction performance stanol fatty acid esters in female decrease in weight of high-dose group.
and variety of reproductive Wistar rats fed at levels of 0, 1.75, No effects on reproductive variables
parameters; malformations 4.38 and 8.76% from day 0 to 21 of and malformation or development
gestation
Effects of soyabean and sheanut 76 healthy adult subjects with mean Soyabean oil steroids, but not sheanut Sierksma et al.20
oil sterols on plasma lipids plus age of 44 (SD 11) years and total oil steroids significantly lowered total 
α- and β-carotene, lycopene cholesterol below 8 mmol/l ingested and LDL cholesterol (3.8 and 6%). No 
0.8 g plant sterols daily in a double- effects on HDL cholesterol. Plasma lipid 
blind cross-over study, comparing standardised α- and β-carotenes not 
effects of sterols from soyabean and significantly influenced, but lycopene 
sheanut oils, added to margarines levels (also standardised) showed a 
9.5% significant reduction
w/w = weight of solute in weight of solvent; LDL = low-density lipoprotein; SD = standard deviation.
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lower IHD risk. Their results from the prospective studies
which included about 500 000 men and 18 000 IHD events,
showed that a long-term reduction of 0.6 mmol/l (10%) in
serum cholesterol concentration, will lower relative risk of IHD
by 50% at age 40. At 50 years of age the reduction is 40%, 30%
at 60 years and 20% at age 70 and older. The randomised trials,
based on data from 45 000 men and 4 000 IHD events, showed
that the full benefit of the reduction in relative risk is achieved
by 5 years. The data for women were limited but indicated a
similar effect.
Based on what is known about the safety of the product, the
recommended target market should include adult, non-
pregnant and non-lactating individuals with raised blood
cholesterol concentrations and/or increased risk of IHD. This is
in agreement with a statement for health care professionals
from the American Heart Association (AHA).40 The AHA also
advises that the product can be used for secondary prevention
after an atherosclerotic event, and that if it is considered for use
in hypercholesterolaemic children, lipid-soluble vitamin status
should be monitored. Before really long-term safety studies
have been completed, routine ingestion by the general
population to lower IHD risk is not advised.
At present the high price of the spread will probably dictate
the target market – affluent people who are aware of their
blood cholesterol level and IHD risk. But the future scenario in
South Africa may change. As more people become urbanised
and prosperous the known social drift phenomenon44 may
result in lower risk in the high socio-economic groups and
higher risk in the lower socio-economic groups. Hopefully at
that stage this functional food will be more affordable to those
who need it most.
Although the safety of these products with added plant
sterols has been evaluated extensively, no data on long-term
safety are available. The situation is similar to that experienced
with the introduction of polyunsaturated fatty acid (PUFA)
diets. In contrast to Mediterranean people who consumed high
mono-unsaturated fatty acid diets for generations, no
populations following high PUFA diets for similar periods
were available to assess long-term effects of PUFAs. Therefore,
it is necessary to establish a post-marketing surveillance system
or safety net45 to monitor long-term effects of this functional
food.
At present all available evidence indicates that proven
benefits far outweigh possible hazards. The food or nutrient
function claim on the South African product is that it contains
plant sterols which actually lower cholesterol and that it is
approved as part of the Heart Foundation eating plan. With
long-term surveillance and more research, a future health claim
Table II. Comparison of nutritional information* and price† of some South African spreads
Flora tub Rama
Nutrients per margarine Rama tub block/brick
100 g Pro-activ (extra light) margarine margarine Butter
Energy (kJ) 1 351 1 354 2 995 2 995 3 040
Protein (g) 0.1 0.33 0.5
Carbohydrate (g)
Total fat 35.0 35.0 80 80 81.8
Saturated fat (g) 8.0 9.0 18.92 47.77
Cholesterol (mg) 21.9
Trans fatty acids (g) 0.5 0.0 1.0 23.81 5.26
Unsaturated fat (g)
MUFA (g) 9.0 8.0 42.0 20.56
PUFA (g) 17.5 18.0 17.34 1.61
Plant sterols (g) 8
Sodium (g) 0.35 0.805 0.802 0.826
Vitamin A (mg RE) 691 691 691 753 (salted
or unsalted)
Vitamin D (mg) 6 6 6 0.76
Vitamin E (mg TU) 66 5 5 1.58
Fibre 0.3 0.0
Moisture (%) 59 15.2 15.7
Price per 100 g 6.796 1.898 1.598 1.098 2.978
* Margarines (spreads) as given in the table, and butter according to South African Food Composition Tables.41,42
† Calculated for 100 g in rands; bought in 500 g or 250 g packs (Pro-activ) at Pick & Pay in December 2000 in Potchefstroom.
RE = retinol equivalents; TU = tocopherol units.
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that it reduces risk of IHD and other cardiovascular diseases
seems promising.
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1. Functional foods are designed and developed to promote health
and/or to reduce disease risk.
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4. Existing evidence shows that plant sterols significantly lower 
total and LDL-cholesterol levels, without affecting HDL-
cholesterol or triglycerides. 
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[b] false
5. Plant sterols are a normal dietary constituent.
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7. Plant sterols effectively lower serum cholesterol levels because 
they inhibit absorption of both exogenous and endogenous cho-
lesterol in the small gut. 
[a] true
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8. Because of their mechanism of action, plant sterols have no 




9. Individuals with a genetic defect resulting in increased 
absorption of plant sterols may develop sitosterolaemia and 




10. The safety evaluation of margarines with added plant sterols 




11. Margarines with added plant sterols are so safe and effective 
that routine ingestion by the general population is advised.
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12. Pregnant and lactating women, even when they are 
hypercholesterolaemic, are advised not to consume products 
fortified with plant sterols.
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